HK1200824A1 - 被取代的苯基唑衍生物 - Google Patents

被取代的苯基唑衍生物

Info

Publication number
HK1200824A1
HK1200824A1 HK15101292.6A HK15101292A HK1200824A1 HK 1200824 A1 HK1200824 A1 HK 1200824A1 HK 15101292 A HK15101292 A HK 15101292A HK 1200824 A1 HK1200824 A1 HK 1200824A1
Authority
HK
Hong Kong
Prior art keywords
substituted
phenylazole derivative
derivative
substituted phenylazole
phenylazole
Prior art date
Application number
HK15101292.6A
Other languages
English (en)
Inventor
Shigeo Yamanoi
Hidenori Namiki
Yuichi Ochiai
Madoka Hoshino
Koji Matsumoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1200824A1 publication Critical patent/HK1200824A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK15101292.6A 2012-01-18 2015-02-05 被取代的苯基唑衍生物 HK1200824A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (ja) 2012-01-18 2013-01-17 置換フェニルアゾール誘導体

Publications (1)

Publication Number Publication Date
HK1200824A1 true HK1200824A1 (zh) 2015-08-14

Family

ID=48799224

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15101292.6A HK1200824A1 (zh) 2012-01-18 2015-02-05 被取代的苯基唑衍生物
HK16108406.3A HK1220448A1 (zh) 2012-01-18 2015-02-05 用於治療糖尿病的 -苯基- -噁唑及 -苯基- -噁二唑衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16108406.3A HK1220448A1 (zh) 2012-01-18 2015-02-05 用於治療糖尿病的 -苯基- -噁唑及 -苯基- -噁二唑衍生物

Country Status (21)

Country Link
US (3) US9233958B2 (zh)
EP (2) EP2805941B1 (zh)
JP (2) JP6104181B2 (zh)
KR (1) KR20140113688A (zh)
CN (1) CN104159892A (zh)
AU (1) AU2013210394A1 (zh)
BR (1) BR112014017656A2 (zh)
CA (1) CA2861847A1 (zh)
CO (1) CO7020920A2 (zh)
ES (2) ES2602962T3 (zh)
HK (2) HK1200824A1 (zh)
IL (1) IL233682A0 (zh)
IN (1) IN2014MN01442A (zh)
MX (1) MX2014008790A (zh)
NZ (1) NZ627303A (zh)
PH (1) PH12014501646A1 (zh)
RU (1) RU2014133738A (zh)
SG (1) SG11201404026SA (zh)
TW (1) TWI551590B (zh)
WO (1) WO2013108800A1 (zh)
ZA (1) ZA201405108B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861847A1 (en) 2012-01-18 2013-07-25 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
EP3766879A1 (en) * 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
CA2549955A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
ZA200610650B (en) * 2004-05-25 2009-04-29 Metabolex Inc Substituted triazoles as modulators of PPAR and methods of their preparation
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP1910290A2 (en) 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
BRPI0616457A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-1,2 oxadiazolona com grupo fenila, bem como seu uso, composição farmacêutica compreendendo os mesmos e seu processo de preparação
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
NZ585284A (en) 2007-10-16 2011-03-31 Daiichi Sankyo Co Ltd Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
WO2010119881A1 (ja) 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
US8557802B2 (en) * 2009-08-05 2013-10-15 Daiichi Sankyo Company, Limited Amide derivative
BR112012002293A2 (pt) * 2009-08-05 2016-06-14 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso do composto
SG189320A1 (en) * 2010-10-14 2013-05-31 Daiichi Sankyo Co Ltd Acylbenzene derivative
RU2014102743A (ru) * 2011-07-29 2015-09-10 Дайити Санкио Компани, Лимитед Амидное производное, замещенное n-гетероциклическим кольцом
CA2861847A1 (en) 2012-01-18 2013-07-25 Daiichi Sankyo Company, Limited Substituted phenylazole derivative

Also Published As

Publication number Publication date
CO7020920A2 (es) 2014-08-11
CN104159892A (zh) 2014-11-19
EP2805941A4 (en) 2015-08-05
TWI551590B (zh) 2016-10-01
EP3009433A1 (en) 2016-04-20
KR20140113688A (ko) 2014-09-24
RU2014133738A (ru) 2016-03-10
JP2017052800A (ja) 2017-03-16
AU2013210394A1 (en) 2014-08-14
MX2014008790A (es) 2014-10-13
HK1220448A1 (zh) 2017-05-05
US9233958B2 (en) 2016-01-12
US20160081993A1 (en) 2016-03-24
ZA201405108B (en) 2015-10-28
NZ627303A (en) 2015-11-27
TW201335141A (zh) 2013-09-01
EP3009433B1 (en) 2017-06-21
EP2805941A1 (en) 2014-11-26
ES2640667T3 (es) 2017-11-03
US9725438B2 (en) 2017-08-08
IN2014MN01442A (zh) 2015-07-03
SG11201404026SA (en) 2014-11-27
US20140357675A1 (en) 2014-12-04
JPWO2013108800A1 (ja) 2015-05-11
WO2013108800A1 (ja) 2013-07-25
BR112014017656A2 (pt) 2017-06-27
US20160090375A1 (en) 2016-03-31
PH12014501646A1 (en) 2014-10-13
ES2602962T3 (es) 2017-02-23
EP2805941B1 (en) 2016-08-17
CA2861847A1 (en) 2013-07-25
IL233682A0 (en) 2014-09-30
JP6104181B2 (ja) 2017-03-29
AU2013210394A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1248702A1 (zh) 取代的吡咯烷-2-甲酰胺
HK1200830A1 (zh) 取代的吡咯烷- -甲酰胺
HK1205740A1 (zh) 吡咯並三嗪酮衍生物
HK1207375A1 (zh) 呱啶基吡唑並吡啶衍生物
HK1207363A1 (zh) 新型茚滿磺酰胺衍生物
HK1206724A1 (zh) 取代的苯並噻吩並嘧啶
AP2015008347A0 (en) Oxazolidin-2-one-pyrimidine derivatives
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh) 取代的咪唑並噠嗪
HK1200824A1 (zh) 被取代的苯基唑衍生物
PT2873660T (pt) Derivado de indolecarboxamida
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HK1204621A1 (zh) -烷酰基氨基- -吡唑啉酮衍生物